Cygnal Poll: A Third of Voters Are in the GLP-1 Market. Republicans Lead Use.

WASHINGTON, D.C. (July 20, 2026) – Cygnal released new data on voters’ views and use of GLP‑1 medications from our July National Voter Trends (NVT) poll of 1,500 likely general election voters (conducted June 30 – July 1). 

“The picture that emerges is of voters layering new tools on top of work they were already doing to increase their overall health,” said Alex Tarascio, Principal and Pollster at Cygnal. “Older voters are treating GLP‑1s more like medicine, younger voters are using them more for how they look and feel, and both groups sit on top of a base of diet, exercise, and trial‑and‑error. For any company in the GLP‑1 space, that means you are not talking to a single ‘vanity’ market, you are talking to distinct segments who see these drugs as one more lever they can pull in a broader effort to lose weight or stay healthy.” 

Data vs. Dogma: 

• Dogma: GLP‑1s are framed as high‑priced “vanity” drugs for affluent, coastal patients and celebrities rather than a broad medical and voter story. 

• Data: Usage rises with income, but Republicans lead among current use 20 percent to 16 percent over Democrats, and 35 percent of voters either use, have used, or are considering a GLP‑1. Among voters earning $75,000 or more, 20 percent currently take a GLP‑1 compared with 13 percent under $75,000, and 38 percent of women are GLP‑1‑interested with men close behind at 31 percent. 

Top Takeaways: 

“The assumption is that GLP-1s are just vanity drugs for the affluent, but the data says otherwise,” Tarascio said. “More Republicans are current users than Democrats. A third of the electorate is already in this market, and two thirds of voters support Medicare covering the drugs. The vanity drug caricature falls apart when you look at who’s actually using GLP-1s and who wants them covered. These are mainstream drugs now used across both parties, by people who have already used diet and exercise to stay healthy. It gives campaigns, health plans, and companies a chance to better understand what motivates people instead of making assumptions.”  

• A third of voters are in the GLP‑1 universe.
  Seventeen percent of likely voters are currently taking a GLP‑1, 8 percent have taken one in the past, and 10 percent are considering it, for a total of 35 percent with direct use or interest. Usage rises with income (20 percent among voters earning $75,000 or more versus 13 percent under $75,000) and spans both parties, with Republicans leading current use 20 percent to 16 percent over Democrats. 

• Minimal stigma, strong support for Medicare coverage.
  Forty‑six percent call GLP‑1 use a personal choice and 12 percent call it a smart, responsible choice, while 32 percent say it is an easy way out or risky, a view concentrated among Trump 2024 voters and swing voters rather than the broader electorate. Medicare coverage of GLP‑1s for weight loss wins 65 percent support with a +45 net margin, including Democrats at +63, Republicans at +30, seniors at +52, and even non‑users and non‑considerers at +27, with strong opposition capped at 13 percent among very conservative voters. 

• Safety concerns are about distance, not just ideology.
  Thirty‑six percent of voters say GLP‑1s are safe, 31 percent say dangerous, and 33 percent are unsure. Current users see them as safe by a +71 net margin, while non‑GLP‑1 voters describe them as dangerous by 24 points and are more likely to be unsure, and women are more likely than men to see risk (35 percent versus 27 percent), highlighting a clear audience for safety reassurance. 

• Two distinct GLP‑1 customer segments.
  Among current users and considerers, 31 percent say their main reason is combined weight and health, 30 percent cite weight alone, 27 percent point to diabetes, and 11 percent to heart disease. Voters 55 and older are more likely to cite diabetes at 36 percent, while younger voters are more likely to choose weight loss, giving companies, providers, and policymakers separate preventive and appearance driven markets to plan around. 

• GLP‑1s supplement effort rather than replace it.
  Sixty percent of voters say they have tried diet to manage weight and 58 percent say exercise, and 88 percent of GLP‑1 triers report having tried at least one of those. Voters who are not open to GLP‑1s are 18 points less likely to have tried diet or exercise and 8 points more likely to say they have tried nothing, which undercuts the “easy way out” stereotype. 

“GLP‑1s are now part of how people think about their monthly budget and their, not just a story they see on TV or social media,,” said Brent Buchanan, Founder and CEO of Cygnal. “Voters are comparing  what they hear about these drugs to what they  and in their friends can actually afford, and that pulls the debate out of the culture war lane and onto the kirchen table, especially when they see stories about insurance and Medicare coverage. Any party that wants to lead on health policy now has to decide whether GLP‑1s are something they want to make easier to access.” 

“Most people have begun to understand that treating obesity is real medical care, and it’s good to see the data reflect that. Obesity is a chronic disease, and the patients I see have usually worked at this for years before they reach for a medication. A GLP-1 is one effective tool, and the care around it, the ongoing follow-up, is what turns it into real results,” said Dr. Jessica Duncan, Chief Medical Officer of Ivim Health and a board-certified obesity medicine physician. 

### 

Led by CEO and pollster Brent Buchanan, author of America’s Emotional Divide, Cygnal is an award-winning international public opinion and predictive analytics firm that has revolutionized the polling industry with multi-mode polling, message mapping, and emotional analytics. Recognized as the #1 private pollster by the Silver Bulletin and The New York Times, the firm boasts an impressive 95 percent accuracy rating in the 2024 election cycle. With experience in all 50 U.S. states and over 20 countries, Cygnal has strategically guided over 3,100 campaigns and conducted more than 4,800 polls. Its client roster includes high-profile figures such as Governors Greg Abbott and Brian Kemp, along with numerous other Members of Congress, state legislators, caucuses, corporations, and trade associations, solidifying Cygnal as a clear leader in political polling and analytics.